Number of the records: 1
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Title Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial Author info Sufliarsky J. ... [et al.] Co-authors Šufliarsky Jozef
Corporation Redakcia Onkológia
Note The Lancet resporatory medicine, vol. 6, no. 6 (2018), s. 431-441 Sign. C 3069 Source Onkológia. - ISSN 1336-8176. - Bratislava : SOLEN , 2018 . - Roč. 13, č. 3 (2018), s. 222-223 MeSH Subject sarkóm : farmakoterapia
kináza anaplastického lymfómu : antagonisty a inhibítory
skúšanie klinické, fáza II, ako téma
výsledok liečby
účinky liekov vedľajšie a nežiaduce reakcie liekov
Subj. Headings krizotinib * nádory inflamatórne myofibroblastické Language English Country Slovak Republic Document kind Rozpis článkov z periodík Database ARTICLES 
article
Number of the records: 1